

Timothy J Nelson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4245221/timothy-j-nelson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

4,208
citations

33
h-index

63
g-index

109
ext. papers

4,961
ext. citations

6.4
avg, IF

5.38
L-index

#	Paper	IF	Citations
98	Chronic cortisol differentially impacts stem cell-derived astrocytes from major depressive disorder patients. <i>Translational Psychiatry</i> , 2021 , 11, 608	8.6	1
97	Identifying gaps in parental support for families of children with hypoplastic left heart syndrome. <i>Cardiology in the Young</i> , 2021 , 1-8	1	0
96	Clinical Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome After Bidirectional Cavopulmonary Anastomosis. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021 , 33, 791-801	1.7	3
95	From Safety to Benefit in Cell Delivery During Surgical Repair of Ebstein Anomaly: Initial Results. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	1
94	Cone Reconstruction for Ebstein Anomaly: Ventricular Remodeling and Preliminary Impact of Stem Cell Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 3053-3061	6.4	1
93	Addressing Variability and Heterogeneity of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1212, 1-29	3.6	12
92	Challenging misinformation and engaging patients: characterizing a regenerative medicine consult service. <i>Regenerative Medicine</i> , 2020 , 15, 1427-1440	2.5	10
91	m.3243A > G-Induced Mitochondrial Dysfunction Impairs Human Neuronal Development and Reduces Neuronal Network Activity and Synchronicity. <i>Cell Reports</i> , 2020 , 31, 107538	10.6	25
90	Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome. <i>ELife</i> , 2020 , 9,	8.9	9
89	Human Induced Pluripotent Stem Cell-Derived Non-Cardiomyocytes Modulate Cardiac Electrophysiological Maturation Through Connexin 43-Mediated Cell-Cell Interactions. <i>Stem Cells and Development</i> , 2020 , 29, 75-89	4.4	12
88	Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. <i>Cell Stem Cell</i> , 2020 , 27, 574-589.e8	18	34
87	Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. <i>Circulation</i> , 2020 , 142, 1605-1608	16.7	14
86	Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
85	Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. <i>Molecular Psychiatry</i> , 2019 , 24, 795-807	15.1	28
84	Studying treatment resistance in depression using patient derived neurons in vitro. <i>Molecular Psychiatry</i> , 2019 , 24, 775-775	15.1	1
83	Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. <i>Molecular Psychiatry</i> , 2019 , 24, 808-818	15.1	38
82	Single-Cell RNA-Sequencing and Optical Electrophysiology of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Discordance Between Cardiac Subtype-Associated Gene Expression Patterns and Electrophysiological Phenotypes. <i>Stem Cells and Development</i> , 2019 , 28, 659-673	4.4	18

81	Hypoplastic left heart syndrome: From bedside to bench and back. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 135, 109-118	5.8	16
80	Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 1614-1623	15.7	25
79	Model system identification of novel congenital heart disease gene candidates: focus on RPL13. <i>Human Molecular Genetics</i> , 2019 , 28, 3954-3969	5.6	6
78	NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered Cardiogenesis. <i>Stem Cells</i> , 2017 , 35, 1106-1119	5.8	23
77	Current Interventional and Surgical Management of Congenital Heart Disease: Specific Focus on Valvular Disease and Cardiac Arrhythmias. <i>Circulation Research</i> , 2017 , 120, 1027-1044	15.7	35
76	Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality. <i>Stem Cells Translational Medicine</i> , 2017 , 6, 1829-1839	6.9	2
75	Disease modeling studies using induced pluripotent stem cells: are we using enough controls?. <i>Regenerative Medicine</i> , 2017 ,	2.5	7
74	Mapping transcriptome profiles of in vitro iPSC-derived cardiac differentiation to in utero heart development. <i>Genomics Data</i> , 2016 , 7, 129-30		1
73	Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 1375-1379	6.9	20
72	Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells. <i>Human Molecular Genetics</i> , 2016 , 25, 254-65	5.6	63
71	Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming 2016 , 41-64		
70	Stem Cell Therapy and Congenital Heart Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2016 , 3,	4.2	3
69	Natural underlying mtDNA heteroplasmy as a potential source of intra-person hiPSC variability. <i>EMBO Journal</i> , 2016 , 35, 1979-90	13	50
68	Regenerative medicine - From stem cell biology to clinical trials for pediatric heart failure. <i>Progress in Pediatric Cardiology</i> , 2016 , 43, 87-89	0.4	
67	Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome. <i>Human Genetics</i> , 2015 , 134, 1003-11	6.3	42
66	Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 195-206	6.9	20
65	Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015 , 149, e35-7	1.5	46
64	Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery. <i>Regenerative Medicine</i> , 2015 , 10, 773-83	2.5	5

63	Ebstein anomaly review: what's now, what's next?. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1101-9	2.5	50
62	Nos3 ^{-/-} iPSCs model concordant signatures of in utero cardiac pathogenesis. <i>Journal of Molecular and Cellular Cardiology</i> , 2015 , 87, 228-36	5.8	3
61	Systems-based technologies in profiling the stem cell molecular framework for cardioregenerative medicine. <i>Stem Cell Reviews and Reports</i> , 2015 , 11, 501-10	6.4	4
60	Time course transcriptome data analysis for in vitro modeling of dilated cardiomyopathy using patient-derived induced pluripotent stem cells. <i>BMC Bioinformatics</i> , 2015 , 16, P8	3.6	78
59	Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 50	8.3	25
58	Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	18
57	Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity. <i>Stem Cells</i> , 2014 , 32, 2350-9	5.8	10
56	Transcriptome from circulating cells suggests dysregulated pathways associated with long-term recurrent events following first-time myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 74, 13-21	5.8	53
55	The inferred cardiogenic gene regulatory network in the mammalian heart. <i>PLoS ONE</i> , 2014 , 9, e100842	3.7	8
54	Transcriptional atlas of cardiogenesis maps congenital heart disease interactome. <i>Physiological Genomics</i> , 2014 , 46, 482-95	3.6	32
53	Embryonic Decellularized Cardiac Scaffold Supports Embryonic Stem Cell Differentiation to Produce Beating Cardiac Tissue. <i>ISRN Stem Cells</i> , 2014 , 2014, 1-10		6
52	Stem cells: the pursuit of genomic stability. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 20948-673		22
51	Heart Regeneration: The Developmental and Stem Cell Biology Approach 2014 , 457-477		
50	Rbm20-deficient cardiogenesis reveals early disruption of RNA processing and sarcomere remodeling establishing a developmental etiology for dilated cardiomyopathy. <i>Human Molecular Genetics</i> , 2014 , 23, 3779-91	5.6	42
49	Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy. <i>Stem Cells and Development</i> , 2014 , 23, 2274-82	4.4	21
48	iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 667-76		8
47	Patients with heart failure have an increased risk of incident cancer. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 881-6	15.1	95
46	New and TALEnted genome engineering toolbox. <i>Circulation Research</i> , 2013 , 113, 571-87	15.7	43

45	Metabolome and metaboproteome remodeling in nuclear reprogramming. <i>Cell Cycle</i> , 2013 , 12, 2355-65	4.7	28
44	Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 10-21	3.3	43
43	Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS. <i>Stem Cells</i> , 2013 , 31, 1298-308	5.8	94
42	Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. <i>Journal of Physiology</i> , 2013 , 591, 4335-49	3.9	30
41	Regenerative medicine primer. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 766-75	6.4	32
40	CXCR4+ and FLK-1+ identify circulating cells associated with improved cardiac function in patients following myocardial infarction. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 787-97	3.3	7
39	Mechanical dyssynchrony precedes QRS widening in ATP-sensitive K+ channel-deficient dilated cardiomyopathy. <i>Journal of the American Heart Association</i> , 2013 , 2, e000410	6	16
38	Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 462-71		15
37	Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming 2013 , 505-528		
36	Energy metabolism plasticity enables stemness programs. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1254, 82-9	6.5	67
35	Metabolic plasticity in stem cell homeostasis and differentiation. <i>Cell Stem Cell</i> , 2012 , 11, 596-606	18	439
34	Mitochondria in control of cell fate. <i>Circulation Research</i> , 2012 , 110, 526-9	15.7	68
33	Impedance of novel therapeutic technologies: the case of stem cells. <i>Clinical and Translational Science</i> , 2012 , 5, 422-7	4.9	1
32	Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. <i>Stem Cells Translational Medicine</i> , 2012 , 1, 709-18	6.9	33
31	The science and ethics of induced pluripotency: what will become of embryonic stem cells?. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 634-40	6.4	40
30	Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. <i>Cell Metabolism</i> , 2011 , 14, 264-71	24.6	725
29	Regenerative Chimerism Bioengineered Through Stem Cell Reprogramming 2011 , 445-468		
28	Induced pluripotent stem cells: an emerging theranostics platform. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 648-50	6.1	32

27	Nuclear reprogramming strategy modulates differentiation potential of induced pluripotent stem cells. <i>Journal of Cardiovascular Translational Research</i> , 2011 , 4, 131-7	3.3	20
26	Energy metabolism in nuclear reprogramming. <i>Biomarkers in Medicine</i> , 2011 , 5, 715-29	2.3	48
25	Induced Pluripotent Cells for Myocardial Infarction Repair 2011 , 263-280		
24	Induced pluripotent stem cells: developmental biology to regenerative medicine. <i>Nature Reviews Cardiology</i> , 2010 , 7, 700-10	14.8	110
23	c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. <i>Journal of Cardiovascular Translational Research</i> , 2010 , 3, 13-23	3.3	51
22	SDF-1-enhanced cardiogenesis requires CXCR4 induction in pluripotent stem cells. <i>Journal of Cardiovascular Translational Research</i> , 2010 , 3, 674-82	3.3	16
21	Decoded calreticulin-deficient embryonic stem cell transcriptome resolves latent cardiophenotype. <i>Stem Cells</i> , 2010 , 28, 1281-91	5.8	18
20	ATP-sensitive K(+) channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy. <i>Stem Cells</i> , 2010 , 28, 1355-67	5.8	19
19	Induced pluripotent stem cells: advances to applications. <i>Stem Cells and Cloning: Advances and Applications</i> , 2010 , 3, 29-37	2.6	13
18	Cardiogenic induction of pluripotent stem cells streamlined through a conserved SDF-1/VEGF/BMP2 integrated network. <i>PLoS ONE</i> , 2010 , 5, e9943	3.7	20
17	Stem cells: clinical trials results the end of the beginning or the beginning of the end?. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2010 , 10, 186-201	1.1	11
16	Clinical pharmacology: a paradigm for individualized medicine. <i>Biomarkers in Medicine</i> , 2009 , 3, 679-84	2.3	7
15	KCNJ11 knockout morula re-engineered by stem cell diploid aggregation. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2009 , 364, 269-76	5.8	17
14	iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. <i>Circulation Research</i> , 2009 , 105, 648-56	15.7	92
13	Induced pluripotent reprogramming from promiscuous human stemness related factors. <i>Clinical and Translational Science</i> , 2009 , 2, 118-26	4.9	28
12	Stem cell platforms for regenerative medicine. <i>Clinical and Translational Science</i> , 2009 , 2, 222-7	4.9	65
11	Experimental therapeutics: a paradigm for personalized medicine. <i>Clinical and Translational Science</i> , 2009 , 2, 436-8	4.9	8
10	Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. <i>Stem Cells</i> , 2009 , 27, 1697-705	5.8	23

9	Lineage specification of Flk-1+ progenitors is associated with divergent Sox7 expression in cardiopoiesis. <i>Differentiation</i> , 2009 , 77, 248-55	3.5	23
8	Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. <i>Circulation</i> , 2009 , 120, 408-16	16.7	386
7	Strategies for therapeutic repair: The "R(3)" regenerative medicine paradigm. <i>Clinical and Translational Science</i> , 2008 , 1, 168-171	4.9	51
6	CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. <i>Stem Cells</i> , 2008 , 26, 1464-73	5.8	99
5	Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. <i>Stem Cells</i> , 2008 , 26, 2644-53	5.8	63
4	Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. <i>The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology</i> , 2006 , 288, 1216-24		54
3	SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2005 , 39, 479-89	5.8	78
2	Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. <i>Journal of Biological Chemistry</i> , 2004 , 279, 12598-604	5.4	62
1	Conserved enhancer in the serum response factor promoter controls expression during early coronary vasculogenesis. <i>Circulation Research</i> , 2004 , 94, 1059-66	15.7	19